Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Transcriptomic Profiling of Upper Tract Urothelial Carcinoma: Bladder Cancer Consensus Classification Relevance, Molecular Heterogeneity, and Differential Immune Signatures.
Fontugne J, Xylinas E, Krucker C, Dixon V, Groeneveld CS, Pinar U, Califano G, Bucau M, Verine J, Desgrandchamps F, Hermieu JF, Radvanyi F, Allory Y, Masson-Lecomte A. Fontugne J, et al. Mod Pathol. 2023 Nov;36(11):100300. doi: 10.1016/j.modpat.2023.100300. Epub 2023 Aug 7. Mod Pathol. 2023. PMID: 37558130
International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 2: Grading of Mixed Grade, Invasive Urothelial Carcinoma Including Histologic Subtypes and Divergent Differentiations, and Non-Urothelial Carcinomas.
Paner GP, Kamat A, Netto GJ, Samaratunga H, Varma M, Bubendorf L, van der Kwast TH, Cheng L; Members of the ISUP Bladder Tumor Consensus Panel. Paner GP, et al. Am J Surg Pathol. 2024 Jan 1;48(1):e11-e23. doi: 10.1097/PAS.0000000000002077. Epub 2023 Jun 29. Am J Surg Pathol. 2024. PMID: 37382156
International Society of Urological Pathology Consensus Conference on Current Issues in Bladder Cancer. Working Group 4: Molecular Subtypes of Bladder Cancer-Principles of Classification and Emerging Clinical Utility.
Warrick JI, Al-Ahmadie H, Berman DM, Black PC, Flaig TW, Höglund M, Bubendorf L, van der Kwast TH, Cheng L; Members of the ISUP Bladder Tumor Consensus Panel. Warrick JI, et al. Am J Surg Pathol. 2024 Jan 1;48(1):e32-e42. doi: 10.1097/PAS.0000000000002053. Epub 2023 May 18. Am J Surg Pathol. 2024. PMID: 37199442 Review.
Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial.
Culine S, Harter V, Krucker C, Gravis G, Fléchon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Fontugne J, Allory Y, Pfister C; VESPER Trial Investigators. Culine S, et al. Among authors: fontugne j. Cancers (Basel). 2023 Mar 13;15(6):1742. doi: 10.3390/cancers15061742. Cancers (Basel). 2023. PMID: 36980628 Free PMC article.
Epigenomic mapping identifies an enhancer repertoire that regulates cell identity in bladder cancer through distinct transcription factor networks.
Neyret-Kahn H, Fontugne J, Meng XY, Groeneveld CS, Cabel L, Ye T, Guyon E, Krucker C, Dufour F, Chapeaublanc E, Rapinat A, Jeffery D, Tanguy L, Dixon V, Neuzillet Y, Lebret T, Gentien D, Davidson I, Allory Y, Bernard-Pierrot I, Radvanyi F. Neyret-Kahn H, et al. Among authors: fontugne j. Oncogene. 2023 May;42(19):1524-1542. doi: 10.1038/s41388-023-02662-1. Epub 2023 Mar 22. Oncogene. 2023. PMID: 36944729 Free PMC article.
FGFR3 Mutational Activation Can Induce Luminal-like Papillary Bladder Tumor Formation and Favors a Male Sex Bias.
Shi MJ, Fontugne J, Moreno-Vega A, Meng XY, Groeneveld C, Dufour F, Kamoun A, Viborg Lindskrog S, Cabel L, Krucker C, Rapinat A, Dunois-Larde C, Lepage ML, Chapeaublanc E, Levrel O, Dixon V, Lebret T, Almeida A, De Reynies A, Rochel N, Dyrskjøt L, Allory Y, Radvanyi F, Bernard-Pierrot I. Shi MJ, et al. Among authors: fontugne j. Eur Urol. 2023 Jan;83(1):70-81. doi: 10.1016/j.eururo.2022.09.030. Epub 2022 Oct 21. Eur Urol. 2023. PMID: 36273937 Free article.
Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapies.
Lang H, Béraud C, Cabel L, Fontugne J, Lassalle M, Krucker C, Dufour F, Groeneveld CS, Dixon V, Meng X, Kamoun A, Chapeaublanc E, De Reynies A, Gamé X, Rischmann P, Bieche I, Masliah-Planchon J, Beaurepere R, Allory Y, Lindner V, Misseri Y, Radvanyi F, Lluel P, Bernard-Pierrot I, Massfelder T. Lang H, et al. Among authors: fontugne j. Front Oncol. 2022 Aug 11;12:930731. doi: 10.3389/fonc.2022.930731. eCollection 2022. Front Oncol. 2022. PMID: 36033544 Free PMC article.
Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci.
Fontugne J, Cai PY, Alnajar H, Bhinder B, Park K, Ye H, Beg S, Sailer V, Siddiqui J, Blattner-Johnson M, Croyle JA, Noorzad Z, Calagua C, MacDonald TY, Axcrona U, Bogaard M, Axcrona K, Scherr DS, Sanda MG, Johannessen B, Chinnaiyan AM, Elemento O, Skotheim RI, Rubin MA, Barbieri CE, Mosquera JM. Fontugne J, et al. JCI Insight. 2022 Feb 22;7(4):e155309. doi: 10.1172/jci.insight.155309. JCI Insight. 2022. PMID: 35050902 Free PMC article.
32 results